
We previously described GapMind, an automated web-based tool for annotating amino acid biosynthesis pathways in bacterial and archaeal genomes. We used GapMind to identify gaps in biosynthetic pathways and systematically used comparative genomics and high-throughput genetics to identify candidate genes to fill these gaps. We confirmed the activity of ten of the proposed enzymes by using cross-species complementation assays. Highlights include a route to glycine via glyoxylate, two families that can replace phosphoserine phosphatase, an alternative N-succinyl-L,L-diaminopimelate desuccinylase, an alternative N-acetylornithine deacetylase, and a putative bifunctional MetB/MetC. We updated GapMind to include these additional enzymes. Across 208 prokaryotes that have high-quality genomes and can grow in minimal media, the average number of unexplained missing steps or gaps in amino acid biosynthesis dropped from 1.4 per genome to 0.7 per genome. The majority of remaining gaps involve the gain or loss of phosphate groups.
Neurokinin B (NKB) signaling plays a central role in mammalian thermoregulatory dysfunction associated with menopause, yet the underlying neural mechanisms remain incompletely understood. Here, we establish Caenorhabditis elegans thermotaxis as a genetically tractable system for investigating conserved tachykinin signaling. We demonstrate that overexpression of nlp-58 , the C. elegans ortholog of mammalian NKB, induces abnormal thermotaxis behavior without impairing the temperature response of the thermosensory neurons. NLP-58 is expressed in multiple neurons, including the AIY interneurons, a central integrative node of the thermosensory circuit. AIY-specific overexpression of nlp-58 is sufficient to reproduce the thermotaxis defect, identifying AIY as an important site of NLP-58-dependent behavioral modulation. Genetic analyses further demonstrated that the thermotaxis behavior is mediated primarily through the tachykinin receptor TKR-1, the homolog of mammalian tachykinin 3 receptor (NK3R), acting in ASG and/or ASJ sensory neurons. We also identified a genetic interaction between dhs-4 , a lipid metabolic enzyme gene, and nlp-58 , suggesting that lipid metabolic pathway modulate tachykinin-dependent thermotaxis behavior. Furthermore, endogenous NLP-58/TKR-1 signaling contributed to the age-dependent decline in thermotaxis behavior. Finally, treatment with fezolinetant, a selective NK3R antagonist used clinically for menopausal vasomotor symptoms, partially improved the thermotaxis defect caused by nlp-58 overexpression. Together, our findings identify the NLP-58/TKR-1 signaling pathway as a modulatory component of thermotaxis behavior and provide a framework for investigating conserved principles of tachykinin-dependent circuit modulation.
The relationship between gene expression, DNA methylation, and lung cancer remains elusive in East Asian (EAS) populations. Transcriptome- and methylome-wide association studies (TWAS/MWAS) help uncover gene-trait associations by integrating multi-omics data, yet models trained mainly on European references limit cross-population generalizability. To address this, we developed EAS-specific gene expression and DNA methylation prediction models using whole-blood data from over 800 and 4,300 individuals, respectively. Applying these to lung cancer GWAS from Nanjing Medical University (13,327 cases; 13,328 controls) and Biobank Japan (4,444 cases; 489,012 controls), we identified 25 genes and 42 CpGs associated with lung cancer risk in the discovery stage, with seven genes and 32 CpGs replicated. Three novel genes outside known GWAS loci-RP11-57K17.1 (6q22.31), RP11-313J2.1 (10q11.21), and BMS1P2 (10q11.22)-were identified. In addition, Mendelian randomization analyses suggested that methylation-mediated downregulation of RP11-147L13.11 can reduce lung cancer risk. Our study reveals new susceptibility genes and offers insights into genetic-epigenetic regulatory mechanisms in lung cancer among EAS populations.
Background Individuals with deleterious germline variants in telomerase (encoded by TERT ) are at high risk of pulmonary fibrosis (PF), liver disease (LD), bone marrow failure, head/neck squamous cell carcinoma (HNSCC), and other complications. Clinically ascertained cohorts are subject to biased ascertainment of affected individuals and families with early onset, complex disease. This study used genomic ascertainment to determine prevalence of deleterious TERT variants and the associated risks of telomere biology disorder (TBD) phenotypes. Methods TERT variants were extracted from exome sequencing data in UK Biobank (UKB, 469,377 exomes) and Geisinger-Regeneron DiscovEHR collaboration (DiscovEHR, 170,503 exomes). Cases were individuals with heterozygous deleterious TERT variants classified per modified ACMG/AMP criteria. Controls excluded rare, exonic, and splice site TERT variants. Electronic health records were assessed for TBD-related ICD10 codes. Case-control comparisons were done separately for UKB and DiscovEHR, accounting for smoking, alcohol, BMI, sex, genetic ancestry, and birthyear. Results There were 64 deleterious TERT variants in 203 UKB participants and 32 in 138 DiscovEHR participants. Prevalence estimates were 1:2,312 in UKB and 1:1,235 in DiscovEHR. Risk of PF was significantly increased for TERT heterozygotes compared with controls (UKB: odds ratio [OR] 10.9 95% confidence interval [CI]: 6.11-19.45, p < 0.001; DiscovEHR: OR 6.64, 95% CI: 3.31-13.3, p < 0.001). Deleterious TERT variants were also associated with higher risk of LD (OR 2.4, 95% CI:1.25-4.59, p = 0.038) and HNSCC (OR 5.75, 95% CI: 2.36-14.02, p = 0.001) in UKB but not in DiscovEHR. Conclusions Rare deleterious TERT variants were present in 0.04 to 0.08% of the populations studied. Genomic ascertainment shows a predominance of pulmonary phenotypes, with PF associated with deleterious TERT variants in both cohorts. Associations with LD and HNSCC were observed only in UKB, possibly reflecting cohort differences including healthy volunteer bias. These findings illustrate the clinical importance of genetic diagnosis, and need for TBD-specific clinical trials.